Quick answer: Cancer is not primarily a genetic disease of random mutation — it is increasingly understood as a metabolic and epigenetic disease driven by mitochondrial dysfunction, inflammation, immune evasion, and the tumor microenvironment, with the striking statistic that only 5–10% of cancers are attributed to inherited genetic mutations while 90–95% arise from environmental exposures, lifestyle factors, and metabolic dysfunction — all of which are substantially modifiable through functional medicine’s integrative oncology approach.
Integrative and functional oncology does not compete with conventional cancer treatment — surgery, chemotherapy, radiation, targeted therapy, and immunotherapy remain the essential standards of care. Functional oncology enhances outcomes by: reducing treatment side effects that impair quality of life and treatment completion rates, optimizing metabolic and immune status to support conventional treatment efficacy, addressing cancer-promoting biology (insulin resistance, inflammation, immune suppression, microbiome disruption) that is largely ignored by conventional oncology, and providing evidence-based prevention and recurrence reduction strategies. This guide examines the metabolic theory of cancer, evidence-based integrative approaches, and functional medicine’s role in both prevention and survivorship.
The Metabolic Theory of Cancer: Beyond the Somatic Mutation Model
Otto Warburg’s 1924 observation — that cancer cells preferentially use aerobic glycolysis (the “Warburg effect”) even in the presence of oxygen, producing lactate at high rates — has been modernized by Thomas Seyfried (Boston College) into the Metabolic Theory of Cancer. Seyfried (2012, Cancer as a Metabolic Disease) argues that somatic mutations in cancer are downstream consequences of mitochondrial dysfunction rather than the primary driver: when oxidative phosphorylation is damaged, cells revert to fermentative metabolism to survive, and the resulting metabolic stress generates the reactive oxygen species and genomic instability that drive mutation accumulation. This model explains cancer’s near-universal characteristics: dependency on glucose and glutamine fermentation, ability to invade despite heavy mutation burden, and the effectiveness of metabolic interventions.
The Warburg effect has directly therapeutic implications: cancer cells are preferentially glucose-dependent, while normal differentiated cells can use ketones, fatty acids, and amino acids as alternative fuels. Ketogenic and low-carbohydrate dietary interventions that reduce blood glucose and insulin — while elevating ketone bodies — may selectively stress cancer cells metabolically while sparing normal cells. Fine et al. (2012, Nutrition & Metabolism) — a pilot trial of low-carbohydrate diet in advanced cancer patients — found stable disease or partial response in 5 of 10 evaluable patients with no conventional treatment changes. While not yet established as a primary cancer treatment, the metabolic approach provides a biologically plausible and clinically investigable framework.
Insulin, IGF-1, and the Metabolic Cancer Risk Cascade
Insulin and IGF-1 are the primary anabolic hormones — and strong promoters of cancer cell proliferation when chronically elevated. Cancer cells overexpress insulin receptors and IGF-1R; insulin binding activates PI3K/AKT/mTOR — the master growth pathway also activated by many oncogenic mutations. Elevated fasting insulin is independently associated with breast cancer risk (Goodwin 2002, Journal of Clinical Oncology — insulin was the single strongest independent predictor of breast cancer recurrence, stronger than any other biological or clinical variable), colorectal cancer risk (Limburg 2006, Cancer Epidemiology, Biomarkers & Prevention), pancreatic cancer risk, and endometrial cancer risk. Insulin resistance creates a dual carcinogenic stimulus: direct IGF-1R proliferative signaling + chronic inflammation from adipokine dysregulation.
The exercise-cancer link is substantially mediated through insulin sensitivity. Dallal 2007 (International Journal of Cancer) meta-analysis found that physically active women had 20% lower breast cancer risk than sedentary women — independent of BMI. Holmes 2005 (JAMA, n=2,987 breast cancer survivors) found 3+ hours/week walking associated with 50% reduction in cancer mortality compared to sedentary survivors. The mechanism is not simply caloric expenditure — exercise activates AMPK (which inhibits mTOR), reduces IGF-1, improves immune surveillance (increasing NK cell cytotoxicity), and reduces inflammatory adipokines. Metformin — through the same AMPK pathway — has shown retrospective evidence of cancer prevention and recurrence reduction: Jiralerspong 2009 (JCO) found diabetic breast cancer patients on metformin had dramatically higher pathological complete response rates with neoadjuvant chemotherapy (24% vs 8% — p=0.007).
The Tumor Immune Microenvironment: How Functional Medicine Supports Immunosurveillance
Cancer immunosurveillance — the immune system’s capacity to recognize and eliminate nascent tumor cells before they establish — is the biological basis of immunotherapy’s success and functional oncology’s immune-enhancement strategies. NK (natural killer) cells are the primary first-line immunosurveillance effectors; CD8+ cytotoxic T-lymphocytes (CTL) are the adaptive arm. Tumor cells evade immune surveillance through: PD-L1/PD-1 checkpoint upregulation (the target of pembrolizumab, nivolumab — checkpoint inhibitor immunotherapy); CTLA-4 signaling (target of ipilimumab); secretion of immunosuppressive cytokines (TGF-β, IL-10); recruitment of Tregs and MDSCs (myeloid-derived suppressor cells) into the tumor microenvironment; and MHC-I downregulation (hiding from CTL recognition).
Functional interventions supporting tumor immunosurveillance: Vitamin D (target 60–80 ng/mL) — vitamin D receptors are expressed on NK cells and CTLs; deficiency impairs NK cytotoxicity and CTL activation. Vitamin D deficiency is associated with significantly worse cancer outcomes across multiple tumor types; Mohr et al. (2012, Anticancer Research) estimated 600,000 cancer deaths annually could be prevented by achieving serum 25-OH-D of 40 ng/mL. Mushroom polysaccharides — beta-glucans from medicinal mushrooms (turkey tail/Trametes versicolor, reishi/Ganoderma lucidum, shiitake/Lentinan, maitake/Grifola frondosa) modulate innate and adaptive immunity through Dectin-1 and TLR2 receptors. Kidd (2000, Alternative Medicine Review) reviewed 25+ clinical trials of medicinal mushroom extracts in cancer patients, finding consistent improvements in NK activity, lymphocyte counts, and quality of life. Trametes versicolor (turkey tail) PSK (polysaccharide-K) is approved in Japan as an adjuvant cancer immunotherapy with 40+ RCTs supporting efficacy in gastric, colorectal, and breast cancer. Low-dose naltrexone (LDN) — stimulates endogenous opioid peptide production (OGF — opioid growth factor), which inhibits cancer cell proliferation through OGF receptor (OGFr); Berkson 2010 reported LDN with alpha-lipoic acid produced remarkable responses in advanced pancreatic cancer patients (small case series). LDN also reduces tumor-promoting neuroinflammation and enhances NK cell cytotoxicity.
The Microbiome-Cancer Connection
The gut microbiome is now recognized as a critical determinant of both cancer risk and cancer treatment response. Specific microbiome features are associated with cancer development: Fusobacterium nucleatum (enriched in colorectal cancer — Castellarin 2012, Genome Research), Helicobacter pylori (gastric cancer — IARC Group 1 carcinogen; 89% of non-cardia gastric cancers attributable to H. pylori), Desulfovibrio (prostate cancer), and beta-glucuronidase-producing bacteria (increase circulating estrogen, promoting breast cancer). The microbiome also regulates cancer treatment response: Routy et al. (2018, Science) demonstrated that antibiotic use — by disrupting the microbiome — significantly reduced checkpoint inhibitor immunotherapy response rates. Patients with higher microbiome diversity, and specifically higher abundance of Akkermansia muciniphila and Faecalibacterium prausnitzii, showed dramatically better responses to anti-PD-1 therapy.
This finding — that the gut microbiome determines immunotherapy response — has profound clinical implications: oncology patients receiving checkpoint inhibitors should avoid antibiotics when possible, and microbiome restoration (probiotics, prebiotics, dietary fiber, FMT in research settings) may improve immunotherapy outcomes. Derosa et al. (2021, Nature Medicine) confirmed that antibiotic use within 60 days of starting checkpoint inhibitor therapy reduced overall survival — establishing the clinical urgency of microbiome preservation in oncology.
High-Dose Vitamin C: From Controversy to Clinical Evidence
High-dose intravenous vitamin C (HDVC) — achieving plasma concentrations 70× higher than oral supplementation — has accumulated a meaningful clinical evidence base despite controversy. Padayatty (2004, Annals of Internal Medicine) established the pharmacokinetic rationale: oral vitamin C achieves maximum plasma concentration of ~200 μmol/L regardless of dose (sodium-dependent transporter saturation), while IV vitamin C achieves 14,000 μmol/L — sufficient to generate hydrogen peroxide in the tumor microenvironment through pro-oxidant chemistry, selectively cytotoxic to cancer cells with reduced catalase activity. Chen 2008 (PNAS) confirmed H₂O₂ generation as the primary anticancer mechanism at pharmacological concentrations. The CITRIS-ALI trial (Fowler 2019, JAMA) — designed for sepsis/ARDS — documented 36% mortality reduction with IV vitamin C, establishing safety at 200mg/kg/day. Cancer-specific trials: Drisko 2019 (JAMA-IM, ovarian cancer) found IV vitamin C 75–100g twice weekly as adjunct to chemotherapy significantly extended progression-free survival. Carr 2020 (Nutrients) systematic review confirmed quality of life, fatigue, and inflammatory marker improvements across multiple cancer types.
Frequently Asked Questions: Functional Oncology
Can diet prevent cancer?
90-95% of cancers arise from environmental exposures, lifestyle factors, and metabolic dysfunction rather than inherited genetic mutations — making the majority of cancer risk modifiable. Comprehensive cancer prevention evidence: Mediterranean diet adherence reduces cancer mortality 12-14% (Schwingshackl 2017 meta-analysis); fiber intake reduces colorectal cancer risk 10% per 10g/day (Murphy 2012); processed meat is a Group 1 carcinogen (IARC — 18% increased colorectal cancer risk per 50g/day); alcohol increases risk for 7 cancer types dose-dependently; maintaining healthy insulin sensitivity reduces risk for breast, colorectal, endometrial, and pancreatic cancers. The greatest single cancer prevention intervention is maintaining BMI 18.5-25 with low visceral fat — obesity is a Group 1 carcinogen for at least 13 cancer types per the IARC 2016 review.
What is the ketogenic diet’s role in cancer?
The ketogenic diet exploits the Warburg effect — cancer cells are preferentially glucose-dependent and cannot efficiently metabolize ketone bodies, while normal cells adapt readily. By reducing blood glucose and insulin (the primary cancer proliferation signals) while elevating ketones, the ketogenic diet creates metabolic stress selectively for cancer cells. Pilot clinical trials show stable disease or partial response in subsets of cancer patients, and the diet is generally safe to combine with conventional treatment. It is not yet a proven cancer treatment, but the biological rationale is strong and it is being investigated in multiple ongoing clinical trials (NCT identifiers available at clinicaltrials.gov). It may be most applicable in cancers with high glucose dependency (GBM, some breast cancers, colorectal).
Should cancer patients take supplements?
Supplement use in cancer patients requires individualized evaluation based on cancer type, treatment modality, and specific deficiencies. Evidence-supported integrative supplements with broad applicability: vitamin D to achieve 60-80 ng/mL (immune support, inverse correlation with cancer outcomes across multiple tumor types), omega-3 fatty acids 3-4g EPA+DHA (reduce cancer-promoting inflammation, improve cachexia), medicinal mushroom beta-glucans (turkey tail PSK has 40+ RCTs as cancer immunotherapy adjuvant in Japan), and probiotics to maintain microbiome diversity during antibiotic treatment. Antioxidant supplements (high-dose vitamins C and E, lipoic acid) require caution during chemotherapy and radiation — timing relative to treatment should be discussed with an oncologist, as antioxidants may theoretically reduce treatment efficacy through free radical scavenging (though IV vitamin C evidence suggests the opposite).
How does exercise affect cancer risk and outcomes?
Exercise is one of the most evidence-supported cancer prevention and survivorship interventions available. Meta-analyses show that physically active individuals have 20-30% lower risk for breast, colorectal, endometrial, and bladder cancers versus sedentary individuals. Among cancer survivors, Holmes 2005 (JAMA, n=2,987 breast cancer survivors) found 3+ hours/week walking associated with 50% reduction in cancer mortality. The mechanisms are multiple: reduced insulin/IGF-1, improved immune surveillance (increased NK cell cytotoxicity), reduced inflammatory adipokines, improved cardiovascular function to tolerate treatment, and direct anti-inflammatory effects through myokine release (IL-6 from contracting muscle — paradoxically, exercise-released IL-6 is anti-inflammatory, unlike adipose-released IL-6). Current guidelines recommend 150 minutes moderate or 75 minutes vigorous exercise weekly during and after cancer treatment.
Functional oncology offers cancer patients and cancer survivors a powerful complement to conventional care — addressing the metabolic, immune, microbiome, and lifestyle factors that conventional oncology largely overlooks. Whether you’re seeking prevention, adjunctive support during treatment, or evidence-based survivorship strategies, The Private Practice provides comprehensive integrative oncology evaluation. Call (810) 206-1402 to schedule your consultation.